Search

Displaying results 5101 - 5110 of 10000 in total
  1. Drug

    Sugemalimab

    go.drugbank.com/drugs/DB16641
    ApprovedInvestigational

    to treat T-cell lymphoma. … The antibody has also been granted the Breakthrough Therapy Designation by the FDA to treat relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma (R/R ENKTL) and an orphan drug designation

    Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors
  2. Drug

    Donanemab

    go.drugbank.com/drugs/DB16647
    ApprovedInvestigational

    Donanemab is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against insoluble N-truncated pyroglutamate amyloid beta (Aβ), [L50978] which is found in the brain amyloid plaques that … [A232214] On July 2, 2024, donanemab was approved by the FDA for the treatment of AD in patients with mild cognitive impairment or dementia symptoms.

    Synonyms: IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS APP (AMYLOID BETA A4 PRECURSOR PROTEIN) A BETA 3-PYROGLUTAMYL PEPTIDES, A.BETA. 3 (3-X)), HUMANIZED MONOCLONAL ANTIBODYGAMMA1 HEAVY CHAIN HUMANIZED (1-444) (, Immunoglobulin G1, anti-(human pyroglutamyl Aβ (3-x) peptide)(human clone LY3002813 γ1-chain), disulfide with human clone LY3002813 κ-chain, dimer
  3. Drug

    Orticumab

    go.drugbank.com/drugs/DB16653
    Investigational

    Orticumab is under investigation in clinical trial NCT04776629 (A Proof-of-activity Study With Orticumab in Subjects With Psoriasis and Cardiometabolic Risk Factors).

  4. Drug

    Bentracimab

    go.drugbank.com/drugs/DB16659
    Investigational

    Bentracimab is under investigation in clinical trial NCT04286438 (Bentracimab (PB2452) in Ticagrelor-treated Patients With Uncontrolled Major or Life-threatening Bleeding or Requiring Urgent Surgery or Invasive Procedure).

    Categories: Heterocyclic Compounds, 2-Ring
  5. Drug

    Efanesoctocog alfa

    go.drugbank.com/drugs/DB16662
    ApprovedInvestigational

    Endogenous VWF protects FVIII from degradation but also sets a half-life of approximately 15 to 19 h. … episodes in patients with hemophilia A.

  6. Drug

    Oxelumab

    go.drugbank.com/drugs/DB16663
    Investigational

    Oxelumab is under investigation in clinical trial NCT00983658 (A Study of HuMAb OX40L in the Prevention of Allergen-induced Airway Obstruction in Adults With Mild Allergic Asthma).

  7. Drug

    Pimivalimab

    go.drugbank.com/drugs/DB16667
    Investigational

    Pimivalimab is under investigation in clinical trial NCT04549025 (Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab in Biomarker-selected Subjects With Metastatic NSCLC After

  8. Drug

    Torudokimab

    go.drugbank.com/drugs/DB16671
    Investigational

    Torudokimab is under investigation in clinical trial NCT03831191 (A Study of LY3375880 in Adults With Moderate-to-severe Atopic Dermatitis).

  9. Drug

    Uliledlimab

    go.drugbank.com/drugs/DB16675
    Investigational

    Uliledlimab is under investigation in clinical trial NCT04322006 (A Phase I/II Study of TJ004309 for Advanced Solid Tumor).

  10. Drug

    Tegoprazan

    go.drugbank.com/drugs/DB16690
    Investigational

    [A234215, A234220] This drug is a potent and high-selective potassium-competitive acid blocker (P-CAB) with a fast onset of action and the ability to control gastric pH for a prolonged period of time. … Tegoprazan (also known as CJ-12420) is a novel therapeutic developed by CJ Healthcare Corp for treating acid-related gastrointestinal diseases.

    Categories: Heterocyclic Compounds, 1-RingSynonyms: K-CAB